可能的eculizumab相关的肝毒性在患有光学神经炎的患者:一个病例报告
Koc Emine Rabia1, Turan Ömer Faruk1, Saridas Furkan1
1Department of Neurology, Faculty of Medicine, Uludag University, Bursa, Turkey.
The International journal of neuroscience
|August 26, 2023
概括
用于神经omyelitis optica (NMO) 的eculizumab可能会导致肝损伤. 在治疗期间监测肝功能至关重要,以检测和管理这种罕见的不良事件.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 光学神经炎 (NMO) 是一种严重的自身免疫性中枢神经系统脱髓化疾病.
- 埃奎利祖马布的点补充了C5,在各种自身免疫和补充介导疾病中有效.
- 反AQP4自身抗体是NMO谱系障碍 (NMOSD) 治疗的关键.
研究的目的:
- 报告一个用eculizumab治疗的NMOSD患者潜在的药物诱导肝损伤 (DILI) 的病例.
- 为突出监测NMOSD治疗eculizumab期间肝功能的重要性.
主要方法:
- 一个NMOSD患者的病例报告.
- 开始使用eculizumab治疗.
- 监测肝功能测试 (LFTs) 和临床表现.
主要成果:
- 患者在开始使用eculizumab的三个月后可能出现了药物诱导的肝损伤.
- 肝功能测试在停止治疗eculizumab后的一个月内正常化.
结论:
- 与eculizumab相关的肝毒性是NMOSD中以前未报告的不良事件.
- 对于接受eculizumab的患者来说,常规监测LFT至关重要.
- 如果怀疑肝毒性,请调查肝损伤的其他原因.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


